Poliovirus Receptor anticorps (PE)

N° du produit ABIN2663058

Cet anticorps Rat Monoclonal détecte spécifiquement Poliovirus Receptor dans FACS, IP, IF et BR. Il présente une réactivité envers Souris.

Aperçu rapide pour Poliovirus Receptor anticorps (PE) (ABIN2663058)

Antigène: Poliovirus Receptor (PVR)

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp Poliovirus Receptor est conjugé à/à la PE

Application: Flow Cytometry (FACS), Immunoprecipitation (IP), Immunofluorescence (IF), Blocking Reagent (BR)

Clone: 4-24-1

Détail du produit anti-Poliovirus Receptor anticorps (PE)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG2a kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur Poliovirus Receptor

Antigène: Poliovirus Receptor (PVR)

Autre désignation: CD155

Sujet: Mouse CD155, also known as homolog of polivirus receptor, is the founding member of a subfamily of immunoglobulin-like adhesion receptors (nectins). Mouse CD155 is expressed on a wide variety of cells of hematopoietic origin apart from its existence on the epithelial cells. The engagement of CD155 with CD226 and CD96 induces cytotoxicity of NK cells and CTL.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cell-Cell Junction Organization, Cancer Immune Checkpoints, SARS-CoV-2 Protein Interactome